NASDAQ · Biotechnology

TAOX (TAOX) Stock

$3.42 -1.16% NASDAQ: TAOX Healthcare

Valuation

MetricValue
Price$3.42
Market Cap$11.24M
P/E Ratio-0.52
P/B Ratio0.69
P/S Ratio21.98
EPS (TTM)$-8.81
52-Week High$11.98
52-Week Low$3.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-131.82%
ROA-111.54%
ROCE-40.91%
Gross Margin99.88%
Operating Margin-14.31%
Net Margin-36.15%
Debt/Equity0.00
Current Ratio12.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$0$0$0$0$-9.0M
Net Profit$-13.0M$-6.0M$-6.0M$-13.0M$-29.0M
EPS$-62.75$-20.25$-29.56$0.00$-8.81
Op Margin————-3025.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$36.0M$39.0M$31.0M$18.0M$26.0M
Total Liabilities$2.0M$3.0M$6.0M$11.0M$4.0M
Cash$34.0M$37.0M$29.0M$18.0M$5.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-11.0M$-5.0M$-5.0M$-6.0M
Investing Cash Flow$0$0$-2.0M$-1.0M$-29.0M
Financing Cash Flow$13.0M$1.0M$0$0$0
Net Cash Flow$28.0M$3.0M$-9.0M$-11.0M$-12.0M
Free Cash Flow$-9.0M$-11.0M$-5.0M$-5.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-40.20%
Quick Ratio27.40
Interest Coverage—
Return 1Y-60.50%
Return 3Y-84.14%
Return 5Y-98.46%

Ownership

Insiders Held2.31%
Institutions Held6.29%
Institutions Float Held6.44%
Institutional HolderSharesReport Date
Renaissance Technologies, LLC101,8002026-03-31
Geode Capital Management, LLC88,6442026-03-31
Vanguard Capital Management LLC79,3692026-03-31
Vanguard Fiduciary Trust Co45,4322026-03-31
Summit Financial, LLC43,2752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOLD $2.48 -3.50% -0.56 $55.74M 0.00%
CVKD $2.06 +0.98% -0.78 $6.38M 0.00%
IBIO $1.45 +1.40% -0.91 $22.89M 0.00%
INTS $4.57 +2.70% -0.60 $12.35M 0.00%
ITRMIterum Therapeutics plc $0.03 -10.98% -0.06 $1.60M 0.00%

About TAOX

TAOX is led by CEO Joshua N. Silverman, employs 4 people, headquartered in US, publicly traded since 2025.

TAOX stock trades at $3.42 with a market capitalization of $11.24M. The stock is valued at a price-to-earnings (P/E) ratio of -0.52, price-to-book of 0.69, price-to-sales of 21.98. Over the past 52 weeks the stock has ranged between $3.25 and $11.98, and currently trades 71.5% below its 52-week high.

On profitability, TAOX generates a return on equity (ROE) of -131.82%, return on capital employed of -40.91%, an operating margin of -14.31%, a net profit margin of -36.15%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides